Sex differences in the association between bone mineral density and lipid profiles in people with type 2 diabetes in southwest China Authors: Ying Shi, Qian Liao, Yingxuan Du, Jiao Zuo, Linhan He, Zhilian Mu, Yuan Wang, Jing Xu, Wei Duan, Hui Wang Published: 2026 ABSTRACT AbstractAimsTo explore the relationship between bone mineral density (BMD) and lipid levels among different genders in people with type 2 diabetes (T2D) across Southwest China, potentially providing a reference for future risk stratification research on osteoporosis in this population.MethodsClinical data from 355 people with T2D admitted to Xinqiao Hospital between January 2015 and December 2020 were retrospectively analyzed. The correlation among serum lipid levels and BMD in people with T2D of distinct genders were investigated.ResultsSubgroup analysis revealed a significant interactive effect of sex on the lipid and BMD. Regarding lipid profiles, serum triglyceride (TG) and apolipoprotein E (ApoE) concentrations showed positive correlations with left femoral neck BMD in men with T2D (r = 0.139, r = 0.146, p < 0.05, respectively), and serum lipoprotein-a and ApoE levels were positively correlated with spinal BMD in women with T2D (r = 0.178, p < 0.05; r = 0.231, p < 0.01, respectively). Furthermore, serum high-density lipoprotein (HDL) levels demonstrated a significant positive correlation with serum 25-hydroxyvitamin D concentrations in women with T2D (r = 0.345, p < 0.01). Multivariate logistic regression analysis revealed that serum calcium levels serve as a protective predictor of osteoporosis in men with T2D (p < 0.05). Conversely, apolipoprotein A1 emerged as an independent risk factor for osteoporosis in women with T2D (p < 0.05).ConclusionIn men with T2D, appropriate TG levels were positively associated with bone mass (femoral neck BMD). Among women with T2D, HDL levels were negatively associated with osteoporosis-related markers. ApoE levels are positively correlated with BMD in both sexes.Keywords: Sex difference, Bone mineral density, Lipid, Type 2 diabetes Introduction Type 2 diabetes (T2D) is a chronic metabolic disorder characterized primarily by hyperglycemia and systemic metabolic dysregulation, constituting a significant threat to global health. An estimated 422 million individuals worldwide are affected by this condition, with its prevalence exhibiting a persistent upward trajectory and projections indicate the global T2D population will reach 592 million by 2035 [1]. Diabetes is recognized as a major etiological factor in secondary osteoporosis. Beyond its established microvascular and macrovascular complications, osteoporosis is increasingly acknowledged as a significant complication of diabetes. Individuals with diabetes demonstrate a 0.5 to 2-fold increased risk of osteoporotic fractures compared to the person without diabetes [2]. Nevertheless, osteoporosis in this cohort remains insufficiently recognized and suboptimally managed. The pathophysiological mechanisms linking osteoporosis and diabetes remain incompletely elucidated. Therefore, comprehensive investigation of bone mineral density (BMD) alterations in individuals with diabetes and analysis of their underlying etiological factors are imperative for the effective prevention and management of osteoporosis. Osteoporosis demonstrates significant gender disparities. Compared to women, men experience a later onset of osteoporosis by approximately 10 years, attributable to a slower decline in testosterone and estradiol levels [3]. A meta-analysis conducted by Si et al. reported osteoporosis prevalence rates of 44.8% and 37.0% among women and men with diabetes, respectively [4]. Consequently, gender differences should be comprehensively accounted for when investigating osteoporosis risk factors. Hyperlipidemia is also a common metabolic disorder among individuals with T2D, while osteoporosis frequently coexists with atherosclerosis. Given that dyslipidemia is a key risk factor for atherosclerosis, this suggests a potential relationship between osteoporosis and lipid metabolism. However, the impact of different types of dyslipidemia on osteoporosis and their underlying mechanisms remain incompletely understood. Furthermore, significant gender differences exist in dyslipidemia prevalence. Men under 50 years old exhibit a higher prevalence of hyperlipidemia than women of the same age, potentially due to higher testosterone levels promoting lipid accumulation [5]. Conversely, the incidence of hyperlipidemia increases progressively in women over 50, likely associated with declining estrogen production post-menopause [5]. Consequently, analyzing the correlation BMD and serum lipid profiles in individuals with diabetes stratified by gender may provide preliminary data support for future osteoporosis risk stratification research. In summary, this study was conducted to analyze gender differences in the correlation between BMD and serum lipids in a cohort of individuals with T2D from Southwest China, potentially providing a reference for future risk stratification research on osteoporosis in this population. Subjects, materials and methods General information A retrospective analysis was performed on clinical data from 355 people with T2D admitted to Xinqiao Hospital, Third Military Medical University, between January 2015 and December 2020. The study protocol received approval from the hospital's Medical Ethics Committee (2025-NO.278.01) and complies with the Declaration of Helsinki. Inclusion Criteria: (1) Diagnosis of T2D according to the “Chinese Diabetes Prevention and Treatment Guidelines (2024 Edition)”; (2) Absence of medications known to affect bone metabolism (e.g., corticosteroids); (3) Provision of informed consent. Exclusion Criteria: (1) Type 1 diabetes; (2) Severe dysfunction of major organs; (3) Acute infection, immune system disorders, or malignancy. Among the cohort of 355 people with T2D, 214 were men: 49 with normal bone mass, 85 with reduced bone mass, and 80 with osteoporosis; 141 were women: 14 with normal bone mass, 33 with reduced bone mass, and 94 with osteoporosis (Supplementary Fig. 1). Statistical indicators and testing methods General protocol Upon hospital admission, clinical researchers systematically document participants’ fundamental demographic and clinical characteristics. These encompass chronological age, body mass index (BMI), comprehensive medical history, and precise duration of illness. Serum biochemical analysis Venous blood samples were collected from fasting subjects during morning hours. Serum biochemical parameters were quantified using an automated clinical chemistry analyzer, encompassing fasting blood glucose (FBG), glycated hemoglobin (HbA1c), total cholesterol (TC), triglycerides (TG), lipoprotein a (Lp-a), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), apolipoprotein E (ApoE), high-density lipoprotein cholesterol (HDL), and low-density lipoprotein cholesterol (LDL). Radioimmunoassay was performed to determine parathyroid hormone (PTH) and 25-hydroxyvitamin D (25-OH-VD) concentrations. Electrochemiluminescence immunoassays were employed to quantify bone metabolism markers: calcitonin (CAL), procollagen Ⅰ N-terminal propeptide (PⅠNP), β-Crosslaps (β-CTX), and N-terminal midfragment of osteocalcin (N-MID). BMD measurement BMD was measured at the L2-L4 vertebrae, left femoral neck, and right femoral neck using an AiDXA bone densitometer (Kangrongxin Company). Classification adhered to the “Guidelines for the Diagnosis and Treatment of Primary Osteoporosis (The Osteoporosis and Bone Mineral Disorders Branch of the Chinese Medical Association, 2022 Edition)”. For postmenopausal women and men aged ≥50 years, diagnosis was established based on T-scores, calculated as follows: T-score = standard deviation of (measured BMD value - peak BMD of young adults of the same ethnicity and sex)/(eak BMD of young adults of the same ethnicity and sex). A T-score ≥ −1.0 defines normal bone mass, a T-score between −2.5 and −1.0 indicates osteopenia, and a T-score ≤ −2.5 defines osteoporosis. Conversely, for premenopausal women and men <50 years old, diagnosis is based on Z-score. Z-score = standard deviation of (measured BMD value - mean BMD of age-matched peers of the same ethnicity and sex)/(mean BMD of age-matched peers of the same ethnicity and sex). A Z-score > −2.0 indicates normal bone mass, whereas a Z-score ≤ −2.0 defines osteoporosis. In our cohort, 279 people with T2D (78.6%) were classified using T-score (postmenopausal women and men≥50 years) and 76 (21.4%) using Z-score (premenopausal women and men<50 years). In instances of discordant results across measurement sites, the lowest T-score or Z-score serves as the diagnostic criterion. Statistical methods Statistical analyses were conducted using SPSS version 25.0 (IBM Corp., USA). Quantitative data are presented as mean ± standard deviation (x‾ ± SD). Missing data were handled by a complete-case analysis method. Continuous variables were first tested for normality using Shapiro-Wilk normality test. If the variable exhibited a normal distribution, Student's t-test was applied. Otherwise, Wilcoxon rank-sum test was applied. Relationships between variables were examined using Spearman's rank-order correlation analysis. No formal correction was applied for multiple statistical tests, due to the exploratory nature of the study. Variables with a p-value less than 0.10 in univariate analysis or were deemed clinically relevant (such as age, BMI, and menopausal status) were included in the multivariable logistic regression model using the enter method to identify independent predictors of osteoporosis. Multivariable logistic regression was used to identify independent risk factors for osteoporosis in individuals with T2D. Hosmer-Lemeshow goodness of fit test was used to assess the model fit (Hosmer-Lemeshow statistic≥0.05). A correlation coefficient (r) greater than 0 indicated a positive relationship, whereas an r less than 0 indicated a negative relationship. Statistical significance was defined as a two-tailed p-value <0.05. Results Sample characteristics of different genders and subgroup analyses There were statistically significant differences in age (p < 0.01), BMI (p < 0.05), 25-OH-VD (p < 0.05), TC (p < 0.05), TG (p < 0.05), ApoA1 (p < 0.01), HDL (p < 0.01) and LDL (p < 0.05) levels among people with T2D of different genders. In contrast, no significant differences were identified in FBG, HbA1c, β-CTX, N-MID, PⅠNP, PTH, Lp-a, ApoB, or ApoE between the two groups, as detailed in Supplementary Table 1. Subgroup analyses were performed for age, gender, BMI, smoking, alcohol, fracture history, autoimmune disease, malignant tumor, hormone use, diabetes duration, HbA1c and fasting glucose (Supplementary Fig. 2). There was no significant interaction between the subgroups for each item, except for gender and HbA1c. Correlation between bone turnover markers and BMD in person with T2D of different genders Spearman correlation analysis revealed that serum PⅠNP levels in men with T2D demonstrated significant inverse correlations with BMD at all measured anatomical sites (r = −0.155, p < 0.05; r = −0.249, p < 0.01; r = −0.218, p < 0.01, respectively). Conversely, β-CTX and N-MID levels exhibited inverse correlations with right femoral neck BMD in this cohort (r = −0.136, r = −0.150, p < 0.05, respectively) (Table 1). Among women with T2D, serum β-CTX levels were inversely correlated with spinal BMD (r = −0.184, p < 0.05) (Table 1). Table 1The correlation of bone turnover markers with BMD in men or women with T2D.Table 1β-crossN-MIDPⅠNP25-OH-VDCALPTHr valuep valuer valuep valuer valuep valuer valuep valuer valuep valuer valuep valueMaleSpine BMD−0.1070.12−0.0980.154−0.1550.023*0.0710.298−0.0220.743−0.0180.795Left femoral neck BMD−0.1310.057−0.1160.093−0.2490.000*0.0640.352−0.0300.657−0.0840.223Right femoral neck BMD−0.1360.048*−0.1500.029*−0.2180.001*0.0520.448−0.0160.811−0.0540.435FemaleSpine BMD−0.1840.034*−0.1250.147−0.0830.3410.0170.838−0.0410.6250.0710.404Left femoral neck BMD0.0000.9960.0120.892−0.0350.6850.0480.5740.0440.6070.0040.996Right femoral neck BMD0.0460.6040.0510.5580.0290.7420.1030.227−0.0120.892−0.0650.443*indicates statistical significance (p < 0.05). The correlation of bone turnover markers with BMD in men or women with T2D. *indicates statistical significance (p < 0.05). Correlation between lipid profiles and BMD, bone turnover markers in people with T2D of different genders Spearman correlation analysis indicated that among men with T2D, TG levels exhibited significant positive correlations with left femoral neck BMD and PTH levels (r = 0.139, r = 0.153, p < 0.05, respectively). Serum Lp-a levels demonstrated a positive correlation with β-CTX levels (r = 0.185, p < 0.05). ApoE levels were positively correlated with left femoral neck BMD (r = 0.146, p < 0.05) but inversely correlated with 25-OH-VD levels (r = −0.187, p < 0.01). Furthermore, serum LDL levels showed a positive association with β-CTX levels (r = 0.150, p < 0.05) (Supplementary Table 2, Fig. 1). The correlation of serum lipids (a: TG; b: Lp-a; c: ApoA1; d: ApoE; e: HDL; f: LDL) with BMD in men with T2D. TG: triglycerides; Lp-a: lipoprotein a; ApoA1: apolipoprotein A1; ApoE: apolipoprotein E; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol. In women with T2D, serum Lp-a levels demonstrated a positive correlation with spinal BMD and CAL (r = 0.178, r = 0.205, p < 0.05, respectively). Serum ApoA1 levels were negatively correlated with β-CTX levels (r = −0.185, p < 0.05) and positively correlated with 25-OH-VD levels (r = 0.252, p < 0.01). Serum ApoE levels exhibited a positive correlation with spinal BMD (r = 0.231, p < 0.01). Serum HDL levels showed a negative correlation with β-CTX levels (r = −0.179, p < 0.05) and a positive correlation with 25-OH-VD levels (r = 0.345, p < 0.01) (Supplementary Table 3, Fig. 2). The correlation of serum lipids (a: TG; b: Lp-a; c: ApoA1; d: ApoE; e: HDL; f: LDL) with BMD in women with T2D. TG: triglycerides; Lp-a: lipoprotein a; ApoA1: apolipoprotein A1; ApoE: apolipoprotein E; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol. Notably, a sensitivity analysis restricted to participants aged≥50 years and postmenopausal women was conducted to test the robustness of the observed lipid-BMD and lipid-bone turnover marker associations. The results demonstrated that all significant correlations identified in the overall population remained stable in this subgroup, verifying the reliability of our primary findings. Influencing factors for osteoporosis in people with T2D stratified by gender Considering the possibility of multicollinearity among the selected variables, we tested the variable variance inflation factor (VIF) in the model first. And the values of VIF were significantly lower than 5, which suggests that there were no significant cross-correlations between the independent variables. Multivariate logistic regression analysis identified age as an independent predictor of osteoporosis in people with T2D across both genders. Serum CAL levels emerged as a protective predictor against osteoporosis in men with T2D (p < 0.05) (Table 2). Conversely, ApoA1 constituted an independent risk factor for osteoporosis in women with T2D (p < 0.05) (Table 3). Table 2Results of multivariate logistic regression analysis affecting the occurrence of osteoporosis in men with T2D.Table 2Variateβ valueS.E.Wald χ2 valueOR valuep value95%CIOsteoporosisAge0.0340.0137.5561.0350.006*1.010-1.061Smoke−0.7350.2996.0330.4790.014*0.267-0.862β-cross0.0010.0003.0361.0010.0811.000-1.002CAL−1.7350.8084.8820.1680.027*0.034-0.817ApoE0.1440.0842.9021.1550.0880.979-1.362*indicates statistical significance (p < 0.05). Results of multivariate logistic regression analysis affecting the occurrence of osteoporosis in men with T2D. *indicates statistical significance (p < 0.05). Table 3Results of multivariate logistic regression analysis affecting the occurrence of osteoporosis in women with T2D.Table 3Variateβ valueS.E.Wald χ2 valueOR valuep value95%CIOsteoporosisAge0.1150.03014.8281.1220.000*1.058-1.190BMI0.0060.0051.4461.0060.2290.996-1.017menopause0.7510.7830.9192.1180.3380.456-9.832β-cross0.0000.0000.1511.0000.6981.000-1.001N-MID0.0070.0410.0301.0070.8620.930-1.091PⅠNP0.0010.0150.0041.0010.9490.972-1.03125-OH-VD−0.0220.0270.7020.9780.4020.928-1.030CAL1.4141.7260.6714.1120.4130.140-121.169PTH0.0030.0070.1771.0030.6740.990-1.016TC−0.3130.4410.5030.7320.4780.308-1.735TG0.1720.2380.5221.1880.4700.745-1.895ApoA12.2261.0244.7249.2640.030*1.244-68.966ApoB1.5571.7040.8354.7430.3610.168-133.777ApoE−0.1620.1840.7680.8510.3810.593-1.221*indicates statistical significance (p < 0.05). Results of multivariate logistic regression analysis affecting the occurrence of osteoporosis in women with T2D. *indicates statistical significance (p < 0.05). Discussion T2D and osteoporosis represent significant public health concerns with escalating global prevalence, and they frequently coexist. A meta-analysis conducted by Liu et al. reported a global osteoporosis prevalence of 27.67% among individuals with T2D, alongside significantly higher fracture rates compared to individuals without diabetes [6,7]. These findings underscore the critical importance of managing osteoporosis risk factors in individuals with T2D. However, the pathophysiological mechanisms underlying the interaction between osteoporosis and diabetes remain incompletely elucidated. Current evidence indicates that multiple factors associated with diabetes can disrupt bone homeostasis by impairing osteoclast, osteoblast, and osteocyte function, or by altering bone structural properties [8]. For instance, advanced glycation end products (AGEs) significantly inhibit osteoblast proliferation, promote osteoblast apoptosis, and suppress parathyroid hormone secretion [9]. Insulin exerts an anabolic effect on osteoblasts, promoting their proliferation and differentiation through enhanced activity of Runt-related transcription factor 2 (RUNX2) and stimulating collagen synthesis [10]. Nevertheless, the correlation between diabetic dyslipidemia and osteoporosis remains inconclusive. Furthermore, both dyslipidemia and osteoporosis exhibit significant gender-specific differences. Our study is the primer of its kind to analyze the relationship between lipid profiles and BMD in people with T2D in southwest China, stratified by gender; this may help in developing personalized strategies for the prevention and management of osteoporosis in this population. Spearman correlation analysis demonstrated a significant positive association between serum TG levels and left femoral neck BMD in men with T2D, while no such correlation was observed in women group. This finding aligns with conclusions from Ge B et al. in elderly men populations [11]. Conversely, Khinda et al.‘s study in postmenopausal women identified serum TG as an independent risk predictor of osteoporosis. Furthermore, Kan B et al. reported an inverse correlation between TG levels and BMD in elderly person with cardiovascular disease [12,13]. These collective findings indicate that TG may exhibit differential associations with BMD according to gender and age group. Of note, although statistically significant, the correlation between TG and BMD was weak with a low coefficient of determination (r2), indicating that TG levels explained only a small proportion of BMD variance and thus had limited clinical relevance. Our findings demonstrate a positive correlation between serum Lp-a levels and spinal BMD in women with T2D, aligning with results reported by Skripnikova et al. in postmenopausal women [14]. However, conflicting evidence exists. A prospective cohort study by Xiong et al. found no significant association between Lp-a and fracture risk, potentially attributable to the predominantly genetic determination of Lp-a levels and their limited modulation by lifestyle factors [15]. Conversely, Orozco P et al. observed that elevated plasma Lp-a levels may correlate with reduced BMD in postmenopausal women. They postulated that this association might originate from estrogen's capacity to lower plasma Lp-a concentrations by decelerating its synthesis rate [16]. Consequently, the relationship between Lp-a and osteoporosis in women populations merits further investigation. The findings of this study demonstrate a positive correlation between serum ApoE levels and left femoral neck BMD in men with T2D, as well as between serum ApoE levels and spinal BMD in women T2D group. Preclinical investigations indicate that ApoE exerts a pivotal role in bone mass maintenance by facilitating osteoblast differentiation via the ERK1/2 signaling pathway, while concurrently suppressing osteoclast differentiation through modulation of the c-Fos, NFATc1, and NF-κB pathways [17]. Our study provides preliminary evidence of a potential bone-protective effect of ApoE. Although therapeutic strategies targeting ApoE hold promise as a dual therapy for osteoporosis and hyperlipidemia, the clinical significance of ApoE in the treatment of osteoporosis remains limited due to its weak association. However, in our regression model, the association between ApoE and BMD was not significant. This was likely due to the small sample size or excessive adjustment for confounding or mediating variables, which may have diluted the true effect of the target variable. This also highlights the need for larger-scale confirmatory studies. In this study, serum HDL levels in women with T2D demonstrated a significant inverse correlation with β-cross levels and a significant positive correlation with 25-OH-VD levels. Given that β-cross constitutes a key marker of bone resorption, these findings indicate that HDL may inhibit bone matrix degradation and suppress osteoclastic activity by reducing β-cross concentrations. The relationship between HDL and osteoporosis has yielded inconsistent conclusions in prior research. Xie et al. identified a positive correlation between HDL and lumbar spine BMD in a women cohort aged 20 to 59 years, proposing HDL measurement as a potential reactive biomarker for the early detection of osteoporosis and therapeutic guidance [18]. In contrast, a cross-sectional study by Niu et al. confirmed an inverse association between HDL and BMD, with evidence suggesting modulation of this negative relationship by age, gender, and BMI [19]. Additional studies corroborated a positive HDL-BMD association exclusively in women, while no significant correlation was observed in men [20]. Therefore, we hypothesize that there may be an association between elevated HDL levels and a reduced risk of osteoporosis in women with T2D. However, the precise mechanisms underlying HDL's influence on BMD warrant further in-depth investigation. Of note, our subgroup analysis revealed a significant interactive effect between gender and HbA1c, indicating that glycemic control plays a vital sex-specific regulatory role in the lipid-BMD association among people with T2D. Accumulating clinical evidence supports that hyperglycemia and elevated HbA1c disrupt bone and lipid homeostasis, with distinct metabolic impacts on male and female diabetic patients [21]. Poor glycemic control could inhibit bone formation and resorption, thereby contributing to diabetic osteoporosis in men, while aggravated hyperglycemia in women impairs estrogen-mediated bone metabolism and weakens the beneficial lipid-BMD correlations [22,23]. These findings suggest that isolated gender stratification is insufficient to explain the heterogeneity of lipid-bone metabolism relationships in T2D populations. Joint evaluation of gender and long-term glycemic control is therefore essential for individualized risk assessment and precise management of diabetic osteoporosis. Notably, this study has an important limitation regarding lipid-lowering medication use that warrants emphasis before interpreting the overall findings. We did not systematically collect and adjust for data on lipid-lowering treatments, particularly statin therapy, which constitutes a standard first-line treatment for people with T2D and dyslipidemia. Accumulating clinical and preclinical evidence suggests that statins exert dual regulatory effects on human metabolism: they effectively modulate circulating lipid levels, while also actively regulating bone turnover by mediating osteoblast proliferation, osteoclast activity and bone matrix metabolism, thereby potentially altering BMD [24]. As such, unrecorded statin use may introduce unmeasured confounding effects, interfering with the true association between lipid profiles and bone mineral density and potentially affecting the reliability of our analytical results. Future studies should incorporate detailed data on the type, dosage and duration of lipid-lowering medications to eliminate such confounding factors and further verify the findings of the present study. Study limitations This study has several limitations that should be acknowledged. First, it is a single-center retrospective study with a relatively small sample size, especially in the female subgroup (n = 141), which may reduce statistical power and limit the generalizability; therefore, one should avoid overinterpreting the findings specific to women. However, our cohort represents a real-world, consecutive sample of hospitalized patients with T2D in Southwest China, providing valuable regional data and generating hypotheses for further research. Second, the cross-sectional nature of this study cannot identify causality in the observed associations, and the relationships between lipid parameters and BMD should be interpreted as correlational rather than causal. Third, as an exploratory analysis, no adjustments were made for multiple testing to preserve type I error; thus, the results should be interpreted with caution and need validation in independent studies. And we have provided all exact p-values, which readers to assess the size of the effect. Fourth, our multivariable models were adjusted for age, BMl and menopausal status based on clinical relevanceal and hypothesis of influencing the main outcome. Although our study considered several covariates in the analyses, it is crucial to note that there remains the possibility of residual or unmeasured confounding factors (e.g. physical activity, calcium/vitamin D intake, lipid management, specific medications) that could influence the outcomes. Moreover, the main outcome was osteoporosis classification based on BMD, not the occurrence of fractures. Although BMD is the most used clinical indicator for osteoporosis, the occurrence of fractures represents a more clinically relevant outcome and should be included in future study. Finally, the adoption of different criteria for diagnosing osteoporosis across different age groups may affect the comparability of the results. Conclusions In summary, our findings suggest that serum TG levels are positively associated with femoral neck BMD in men, whereas HDL levels are positively associated with spinal BMD and 25-OH-VD, and inversely associated with bone resorption markers in women with T2D. In Spearman analysis, ApoE was identified as a consistent correlate of higher BMD across both sexes; however, this statistical significance did not persist in multivariable logistic regression models after adjusting for confounding and mediating factors. Despite the lost significance in multivariate models, the consistent univariate correlation still indicates the potential of ApoE as a shared biomarker for osteoporosis risk stratification in T2D populations. These hypothesis-generating findings emphasize the necessity of adopting sex-specific strategies when assessing the relationship between lipid profiles and osteoporosis risk in T2D individuals. Of note, the current study has not delved into underlying mechanisms; its findings are primarily intended to suggest promising avenues for future research. Additional studies will therefore be necessary to elucidate the precise mechanisms involved and to establish any actionable thresholds. Disclosure The authors declare that they have no financial/commercial conflicts of interest. Fundings This work was funded by the National Natural Science Foundation of China (No. U24A20673to HT.Z.), the Young PhD Talents Cultivation Project (No. 2024YQB027to H.W.), the outstanding young talents training of Third Military Medical University (school administration [2016], no. 609 to H.W.), the National Natural Science Foundation of China (No. 82230025to HT.Z.), Chongqing Health Technology Promotion General Program (No. 2026jstg012to H.W.), and National Science Fund for Distinguished Young Scholars (No. 81925007to HT.Z.), Subject-Based Talent Development Special “Open Competition & Lead Assignment” Project of the Second Affiliated Hospital of the Army Medical University (No. 2023XKRC003to HT.Z.). CRediT authorship contribution statement Ying Shi: Formal analysis, Investigation, Methodology, Writing – original draft. Qian Liao: Data curation, Methodology, Writing – review & editing. Yingxuan Du: Data curation, Methodology. Jiao Zuo: Investigation, Methodology. Linhan He: Software, Validation. Zhilian Mu: Validation, Visualization. Yuan Wang: Data curation, Formal analysis. Jing Xu: Conceptualization, Supervision, Writing – review & editing. Wei Duan: Conceptualization, Supervision, Writing – review & editing. Hui Wang: Conceptualization, Funding acquisition, Supervision, Writing – review & editing. Competing interests The authors declare that they have no financial/commercial conflicts of interest. Acknowledgements The authors would like to thank all the participants for participating in this trial. Footnotes Supplementary data to this article can be found online at https://doi.org/10.1016/j.metop.2026.100481. Contributor Information Jing Xu, Email: 13512380018@163.com. Wei Duan, Email: weiduan@tmmu.edu.cn. Hui Wang, Email: hwang1213@tmmu.edu.cn. Supplementary data The following is the Supplementary data to this article: Multimedia component 1 References Associated Data Supplementary Materials Multimedia component 1